News
PRQR
1.930
+0.52%
0.010
Analysts Are Bullish on These Healthcare Stocks: Kodiak Sciences (KOD), ProQR (PRQR)
TipRanks · 15h ago
Weekly Report: what happened at PRQR last week (0810-0814)?
Weekly Report · 18h ago
Cantor Fitzgerald Keeps Their Buy Rating on ProQR (PRQR)
TipRanks · 3d ago
Oppenheimer Keeps Their Buy Rating on ProQR (PRQR)
TipRanks · 3d ago
ProQR: Q2 Earnings Snapshot
Barchart · 3d ago
ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation
TipRanks · 4d ago
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results
TipRanks · 4d ago
Weekly Report: what happened at PRQR last week (0803-0807)?
Weekly Report · 08/10 09:02
At a glance: stocks gapping up premarket
Seeking Alpha · 08/04 11:10
Major Insider Move: ProQR’s CEO Makes Bold Bet on the Company’s Future
TipRanks · 08/04 02:04
ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 Shares
Benzinga · 08/03 20:08
Weekly Report: what happened at PRQR last week (0727-0731)?
Weekly Report · 08/03 09:02
Weekly Report: what happened at PRQR last week (0720-0724)?
Weekly Report · 07/27 09:02
Insider Shake-Up: Paychex, ASE, Verisign, ProQR, Pagseguro
TipRanks · 07/25 13:01
ProQR Director Makes Bold Insider Move With New Share Purchase
TipRanks · 07/22 02:00
Weekly Report: what happened at PRQR last week (0713-0717)?
Weekly Report · 07/20 09:02
Weekly Report: what happened at PRQR last week (0706-0710)?
Weekly Report · 07/13 09:02
ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil
TipRanks · 07/11 13:01
ProQR CEO Makes Bold Insider Move Signaling Strong Confidence
TipRanks · 07/09 02:01
ProQR Therapeutics registers to sell 3.03M ordinary shares for holders
TipRanks · 07/06 20:15
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).